It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Neovascularization is a key factor that contributes to tumor metastasis, and vasculogenic mimicry (VM) is an important form of neovascularization found in highly invasive tumors, including lung cancer. Despite the increasing number of studies focusing on VM, the mechanisms underlying VM formation remain unclear. Herein, our study explored the role of the HIF-1α/NRP1 axis in mediating lung adenocarcinoma metastasis and VM formation. HIF-1α, NRP1 expression, and VM in lung adenocarcinoma (LUAD) patient samples were examined by immunohistochemical staining. Quantitative real-time (qRT-PCR), western blot, transwell assay, wound healing assay, and tube formation assay were performed to verify the role of HIF-1α/NRP1 axis in LUAD metastasis and VM formation. ChIP and luciferase reporter assay were used to confirm whether NRP1 is a direct target of HIF-1α. In LUAD tissues, we confirmed a positive relationship between HIF-1α and NRP1 expression. Importantly, high HIF-1α and NRP1 expression and the presence of VM were correlated with poor prognosis. We also found that HIF-1α could induce LUAD cell migration, invasion, and VM formation by regulating NRP1. Moreover, we demonstrated that HIF-1α can directly bind to the NRP1 promoter located between −2009 and −2017 of the promoter. Mechanistically, MMP2, VE-cadherin, and Vimentin expression were affected. HIF-1α plays an important role in inducing lung adenocarcinoma cell metastasis and VM formation via upregulation of NRP1. This study highlights the potential therapeutic value of targeting NRP1 for suppressing lung adenocarcinoma metastasis and progression.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 The First Affiliated Hospital of Soochow University, Department of Pulmonary and Critical Care Medicine, Suzhou, China (GRID:grid.429222.d) (ISNI:0000 0004 1798 0228); Suzhou Key Laboratory for Respiratory Diseases, Suzhou, China (GRID:grid.429222.d); The Affiliated Huai’an Hospital of Xuzhou Medical University, Department of Respiratory Medicine, Huai’an, China (GRID:grid.429222.d)
2 The First Affiliated Hospital of Soochow University, Department of Pulmonary and Critical Care Medicine, Suzhou, China (GRID:grid.429222.d) (ISNI:0000 0004 1798 0228); Suzhou Key Laboratory for Respiratory Diseases, Suzhou, China (GRID:grid.429222.d); Soochow University, Institute of Respiratory Diseases, Suzhou, China (GRID:grid.263761.7) (ISNI:0000 0001 0198 0694)
3 The Affiliated Huai’an Hospital of Xuzhou Medical University, Department of Respiratory Medicine, Huai’an, China (GRID:grid.263761.7)
4 The First Affiliated Hospital of Soochow University, Department of Pulmonary and Critical Care Medicine, Suzhou, China (GRID:grid.429222.d) (ISNI:0000 0004 1798 0228); Suzhou Key Laboratory for Respiratory Diseases, Suzhou, China (GRID:grid.429222.d)